December 10, 2025 | Shanghai, China — Dr. John Zheng and Dr. Hao Liu, Co-founders of Divamics, were invited to attend the CEO Roundtable hosted by JLABS Shanghai. As a representative company within JLABS, Divamics engaged in in-depth discussions with global experts and biotech leaders from JLABS community about the future of drug discovery and global collaborations in innovative R&D.
Dr. Zheng expressed, “We sincerely appreciate JLABS for continuously building an open innovation ecosystem. Their regular and high-quality roundtable forums provide an excellent platform for us to connect with like-minded enterprises at various stages of development, and more importantly, to engage directly with Johnson & Johnson’s global innovation team. These high-frequency, efficient international exchanges have helped us gain a clearer understanding of the common challenges in global drug discovery and have opened up vast opportunities for collaborative innovation.”
During the presentation, Dr. Zheng shared Divamics’ R&D philosophy, core technical capabilities, and business model. He emphasized the company's unique approach in combining AI and molecular dynamics simulations to address the limitations of traditional drug design based on "static structure assumptions." He highlighted that Divamics' technology could restore the true dynamic behavior of drug molecules in highly flexible molecular systems. This innovative approach is crucial during the Hits-to-PCC (Hit-to-Preclinical Candidate) phase and provides more continuous and interpretable critical data to guide precise drug design.
Divamics also discussed the core value of AI in drug discovery. “AI does not replace medicinal chemistry but enriches the information available to chemists. With the higher-dimensional data provided by AI and molecular dynamics, we aim to transform drug discovery from an experience-driven model to a more engineering-based, iterative process—what we call Drug Engineering,” Dr. Zheng remarked.
Divamics, as a resident company of JLABS Shanghai, looks forward to leveraging this open innovation ecosystem for further international collaborations and to solving the most pressing challenges in new drug development. The company aims to work alongside global scientists to bring transformative therapies to the market and create long-term clinical value.
Contact Information：Media Contact: marketing@divamics.com
About JLABS: JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
